Papers/PMID:42087873
Association of preadmission metformin use and prognosis in patients with sepsis with diabetes: a systematic review and meta-analysis.
Frontiers in endocrinology2026The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
metformin — decreases all-cause mortality
Evidence strength: moderate.Findingreplicated ×1“The results of the meta-analysis with a random-effects model showed that septic patients who received metformin prior to hospitalization had significantly lower mortality compared to those without metformin use (OR, 0.58; 95% CI, 0.44–0.75, P < 0.00001).”
Quoted verbatim from Association of preadmission metformin use and prognosis in patients with sepsis with diabetes: a systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- Adults with diabetes admitted with sepsis; pooled observational cohort studies comparing preadmission metformin users with non-users; mortality horizons pooled across studies (28-day, 30-day, 60-day, 90-day, 365-day, ICU and in-hospital)
Effect 0.58 odds ratio, 95% CI 0.44 to 0.75
Association of preadmission metformin use and prognosis in patients with sepsis with diabetes: a systematic review and meta-analysis.2026PMID:4208787310.3389/fendo.2026.1815219Permalink